CheckMate 274: OS Outcomes for Patients With MIBC

Matthew Galsky, MD, of the Icahn School of Medicine at Mount Sinai, shares the first overall survival (OS) data update on the CheckMate 274 trial, which he gave at the 2024 European Association of Urology Congress.

In this study, adjuvant nivolumab demonstrated OS benefit for patients with high-risk muscle invasive bladder cancer (MIBC), especially in those with PD-L1-positive disease.

Dr. Galsky comments on how to make sense of these results when compared with AMBASSADOR, which did not reach statistical significance for OS.